MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.3 -0.76

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.29

Max

1.32

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+105.38% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-624K 80M
Vorheriger Eröffnungskurs	2.06
Vorheriger Schlusskurs	1.3

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Apr. 2026, 23:26 UTC

Heiße Aktien

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16. Apr. 2026, 20:41 UTC

Wichtige Markttreiber

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16. Apr. 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16. Apr. 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16. Apr. 2026, 23:33 UTC

Market Talk

Wichtige Nachrichtenereignisse

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16. Apr. 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16. Apr. 2026, 22:08 UTC

Ergebnisse

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16. Apr. 2026, 22:06 UTC

Ergebnisse

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Wichtige Nachrichtenereignisse

Basic Materials Roundup: Market Talk

16. Apr. 2026, 20:50 UTC

Market Talk

Ergebnisse

Health Care Roundup: Market Talk

16. Apr. 2026, 20:49 UTC

Ergebnisse

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16. Apr. 2026, 20:43 UTC

Ergebnisse

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

16. Apr. 2026, 20:40 UTC

Market Talk

Ergebnisse

Netflix Says Engagement Quality Hits New High -- Market Talk

16. Apr. 2026, 20:30 UTC

Heiße Aktien

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16. Apr. 2026, 20:25 UTC

Ergebnisse

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16. Apr. 2026, 20:23 UTC

Ergebnisse

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16. Apr. 2026, 20:19 UTC

Ergebnisse

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16. Apr. 2026, 20:17 UTC

Ergebnisse

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16. Apr. 2026, 20:16 UTC

Ergebnisse

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

105.38% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 105.38%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.